Skip to Main Content

Paper Details

Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer.
J Clin Oncol
374
2015
487-gene, BRAF, BRAF V600, BRAF V600-Mutant, BRAF V600-Mutant Colorectal Cancer, BRAF V600-mutant, BRAF-mutant melanoma, Dabrafenib, MEK, Mitogen-activated protein kinase, PATIENTS, PIK3CA, PIK3CA mutations, PTEN, Patient, Patient-derived xenografts, Trametinib, V600, dabrafenib, mCRC, mice, mitogen-activated protein kinase, patient, patients, phosphorylated ERK, trametinib
Author NameAffiliation
Wells A MessersmithMassachusetts General Hospital Cancer Center and Harvard Medical School, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, Angeles Clinic and Research Institute, Sarah Cannon Research Institute at HealthONE, University of Colorado Cancer Center and University of Colorado, Sarah Cannon Research Institute/Tennessee Oncology, University of Texas, MD Anderson Cancer Center, Center for Applied Proteomics and Molecular Medicine, George Mason University
Mariaelena PierobonMassachusetts General Hospital Cancer Center and Harvard Medical School, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, Angeles Clinic and Research Institute, Sarah Cannon Research Institute at HealthONE, University of Colorado Cancer Center and University of Colorado, Sarah Cannon Research Institute/Tennessee Oncology, University of Texas, MD Anderson Cancer Center, Center for Applied Proteomics and Molecular Medicine, George Mason University
Yuchen BaiMassachusetts General Hospital Cancer Center and Harvard Medical School, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, Angeles Clinic and Research Institute, Sarah Cannon Research Institute at HealthONE, University of Colorado Cancer Center and University of Colorado, Sarah Cannon Research Institute/Tennessee Oncology, University of Texas, MD Anderson Cancer Center, Center for Applied Proteomics and Molecular Medicine, George Mason University
Scott KopetzMassachusetts General Hospital Cancer Center and Harvard Medical School, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, Angeles Clinic and Research Institute, Sarah Cannon Research Institute at HealthONE, University of Colorado Cancer Center and University of Colorado, Sarah Cannon Research Institute/Tennessee Oncology, University of Texas, MD Anderson Cancer Center, Center for Applied Proteomics and Molecular Medicine, George Mason University
  • 1 - 4

Datasets

Release 1.2